Cevostamab
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Cevostamab
- anti fcrh5 cd3 bite antibody bfcr4350a
- ANTI-FCRH5/CD3 BITE ANTIBODY BFCR4350A
- bfcr 4350a
- BFCR-4350A
- bfcr4350a
- Bfcr4350a
- BFCR4350A
- BFCR4350A (ANTI-FCRH5/CD3 T-CELL DEPENDENT BISPECIFIC ANTIBODY)
- bfcr4350a anti fcrh5 cd3 t cell dependent bispecific antibody
- bfcr4350a cevostamab
- cevostamab
- Cevostamab
- cevostamab [INN]
- CEVOSTAMAB [USAN]
- Cevostamab [WHO-DD]
- cevostamab inn
- cevostamab usan
- cevostamab who dd
- fcrh5 cd3 t cell dependent bispecific antibody bfcr4350a
- FCRH5/CD3 T CELL DEPENDENT BISPECIFIC ANTIBODY BFCR4350A
- immunoglobulin g1 kappa anti homo sapiens fc receptor like protein 5 fcrl5 bxmas1 fc receptor homolog 5 immune receptor translocation associated protein 2 cd307e antigen and anti homo sapiens t cell surface glycoprotein cd3 epsilon chain cd3e leu 4 epsilon chain cd3e antigen monoclonal antibody bispecific tetravalent gamma 1 heavy chain anti fcrl5 1 450 vh mus musculus ighv2 4 01 77 ighd ighj3 01 91 homo sapiens ighv4 4 08 73 ighd ighj5 01 86 8 7 14 1 120 homo sapiens ighg1 03 ch1 r97 k 217 ch2 n67 g 300 ch3 t26 w 369 121 450 223 214 disulfide with kappa light chain anti fcrl5 1 214 v kappa homo sapiens igkv1 39 01 83 igkj2 01 92 6 3 9 1 107 homo sapiens igkc 01 108 214 229 228 232 231 bisdisulfide with gamma 1 heavy chain anti cd3 1 449 vh homo sapiens ighv1 3 01 83 ighd ighj4 01 8 8 12 1 119 homo sapiens ighg1 03 ch1 r97 k 216 ch2 n67 g 299 ch3 t26 s 368 l28 a 370 y67 w 409 120 449 222 219 disulfide with kappa light chain anti cd3 1 219 v kappa homo sapiens igkv4 1 01 89 igkj1 01 12 3 8 1 112 homo sapiens igkc 01 113 219 produced in cho cells
- IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS FC RECEPTOR-LIKE PROTEIN 5, FCRL5 (BXMAS1, FC RECEPTOR HOMOLOG 5, IMMUNE RECEPTOR TRANSLOCATION-ASSOCIATED PROTEIN 2, CD307E-ANTIGEN)) AND ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN, CD3E (LEU-4 EPSILON CHAIN, CD3E-ANTIGEN)), MONOCLONAL ANTIBODY, BISPECIFIC TETRAVALENT;.GAMMA.1 HEAVY CHAIN ANTI FCRL5 (1-450) (VH (MUS MUSCULUS IGHV2-4*01 (77%) (IGHD)-IGHJ3*01 (91%)/HOMO SAPIENS IGHV4-4*08 (73%) (IGHD)-IGHJ5*01 (86%)) (8.7.14) (1-120)-HOMO SAPIENS IGHG1*03 (CH1(R97>K(217)), CH2(N67>G(300)), CH3(T26>W(369))) (121-450) (223-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN ANTI FCRL5 (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-39*01 (83%) IGKJ2*01 (92%))(6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (108'-214')), (229-228'':232-231'')-BISDISULFIDE WITH .GAMMA.1 HEAVY CHAIN ANTI CD3 (1''-449'') (VH (HOMO SAPIENS IGHV1-3*01 (83%) (IGHD)-IGHJ4*01)) (8.8.12) (1''-119'')-HOMO SAPIENS IGHG1*03 (CH1(R97>K(216'')), CH2(N67>G(299'')), CH3(T26>S(368''), L28>A(370''), Y67>W(409''),)) (120''-449'') (222''-219''')-DISULFIDE WITH .KAPPA. LIGHT CHAIN ANTI CD3 (1'''-219''') (V-KAPPA (HOMO SAPIENS IGKV4-1*01 (89%) IGKJ1*01)) (12.3.8) (1'''-112''')-HOMO SAPIENS IGKC*01 (113'''-219''')); PRODUCED IN CHO CELLS
- recombinant anti fcrh5 x anti cd3 bi specific t cell engager bfcr4350a
- RECOMBINANT ANTI-FCRH5 X ANTI-CD3 BI-SPECIFIC T-CELL ENGAGER BFCR4350A
- ro 7187797
And 3 more, listed on the interactive page.
- CAS registry numbers
- 2249888-53-5
- ChEMBL ID
- CHEMBL4297908
- FDA ingredient codes (UNII)
- P86BHN01VE
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -mab
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Multiple Myeloma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 3
- NCT03275103
- NCT04910568
- NCT05535244
- NCT05583617
- NCT05646836
- NCT05801939
- NCT05927571
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain A
- Type
- Protein
- Sequence
- EVQLVESGPGLVKPSETLSLTCTVSGFSLTRFGVHWVRQPPGKGLEWLGVIWRGGSTDYNAAFVSRLTISKDNSKNQVSLKLSSVTAADTAVYYCSNHYYGSSDYALDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
- Component
- Heavy chain C''
- Type
- Protein
- Sequence
- EVQLVQSGAEVKKPGASVKVSCKASGFTFTSYYIHWVRQAPGQGLEWIGWIYPENDNTKYNEKFKDRVTITADTSTSTAYLELSSLRSEDTAVYYCARDGYSRYYFDYWQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
- Component
- Disulfide bridges
- Sequence
- 22-95 $ 22''-96'' $ 23'-38' $ 23'''-94''' $ 134'-194' $ 139''''-199''' $ 146''-202'' $ 147-203 $ 214'-223 $ 219'''-222'' $ 228''-229 $ 231''-232 $ 263''-323'' $ 264-324 $ 369''-427'' $ 370-428
- Component
- Light chain: D'''
- Type
- Protein
- Sequence
- DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWTSTRKSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSFILRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Light chain: B'
- Type
- Protein
- Sequence
- DIQMTQSPSSLSASVGDRVTITCKASQDVRNLVVWFQQKPGKAPKLLIYSGSYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSPPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Disulfide bridges
- Sequence
- 22-95 $ 22''-96'' $ 23'-38' $ 23'''-94''' $ 134'-194' $ 139''''-199''' $ 146''-202'' $ 147-203 $ 214'-223 $ 219'''-222'' $ 228''-229 $ 231''-232 $ 263''-323'' $ 264-324 $ 369''-427'' $ 370-428
Related records
Trials (11)
- A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
- A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Cevostamab Following CAR T Cell Therapy for RRMM
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
In development for (2)
- Neoplasm Phase 1
- Plasma cell myeloma Phase 2